Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor.

Gilles SallesJenny M H ChenIna ZhangFabio KerbauyJames J WuSally W WadeAna NunesChaoling FengIoana KloosWeimin PengJulia T SniderDylan MacielKeith ChanSam KeepingBijal Shah

Published in: Advances in therapy (2024)

Findings suggest that brexu-cel may offer clinically and statistically significant benefits regarding objective response, complete response, and progression-free survival compared to pirtobrutinib among patients with R/R MCL after prior cBTKi therapy. Given the short follow-up and high degree of censoring in BRUIN, an analysis incorporating updated BRUIN data may provide more definitive overall survival results.

Keyphrases

free survival
acute lymphoblastic leukemia
acute myeloid leukemia
diffuse large b cell lymphoma
multiple myeloma
electronic health record
hodgkin lymphoma
big data
newly diagnosed
squamous cell carcinoma
machine learning
bone marrow
mesenchymal stem cells
radiation therapy
artificial intelligence